Fundraising Fox
Protego Biopharma
San Diego, US · Delaware corporation · 28 employees on LinkedIn · 8 known investors
Find your way into Protego Biopharma
Sign up to see every warm intro you have to Protego Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Protego Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
Founders & leadership
Board
Investors · 8
How we know: Droia Ventures's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: Novartis Venture Fund's portfolio page · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$85M disclosed across 3 of 5 rounds · 2019–2025
- Undisclosed amountseries BDec 2025Source ↗
▶$32.9MraisedDec 2025 · 18 investors · Other Health CareRule 506(b)
- TIM LOHOFFDirector
- EDWARD HURWITZDirector
- HANK MICHAEL PETRASSIExecutive Officer
- JANWILLEM NAESENSDirector
- SAOUSSEN BEN HALIMADirector
- LAURA BRASSDirector
- JEFFERY KELLYDirector
- Brent J. WarnerExecutive Officer, Director
- SHELLEY CHUDirector
- HELEN KIMDirector
- Offering amount
- $130.4M
- Amount sold
- $32.9M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51MraisedOct 2021 · 6 investors · BiotechnologyRule 506(b)
- Richard LabaudiniereExecutive Officer, Director
- Jeffrey KellyDirector
- Edward HurwitzDirector
- Shelley ChuDirector
- Helen KimDirector
- Offering amount
- $51M
- Amount sold
- $51M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedDec 2019 · 3 investors · BiotechnologyRule 506(b)
- XIN JIANGExecutive Officer
- Edward HurwitzDirector
- Jeffery W KellyPromoter
- Richard LabaudiniereDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Protego Biopharma.
In the news
Frequently asked questions
- What does Protego Biopharma do?
- Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
- Who are Protego Biopharma's investors?
- Protego Biopharma's investors include Droia Ventures, Novartis Venture Fund, Digitalis Ventures, Forbion, Lightspeed Venture Partners, MPM BioImpact, Vida Ventures, YK Bioventures.
- How much funding has Protego Biopharma raised?
- Protego Biopharma has disclosed $85M raised across 3 of its 5 known rounds.
- Where is Protego Biopharma headquartered?
- Protego Biopharma is headquartered in San Diego, US.